Contract manufacturing organization

Selexis Appoints Roland Hoffmann-Hecht, PhD, as Chief Business Officer

Retrieved on: 
Tuesday, June 1, 2021
Health, Other Health, Other Science, Research, Science, Pharmaceutical, Biotechnology, Contract manufacturing organization, Pharmaceutical industry, Hecht, Chief business officer, Leadership, Economy, Articles

Selexis SA , a JSR Life Sciences company, has named seasoned business development executive Roland Hoffmann-Hecht, PhD, as its new chief business officer.

Key Points: 
  • Selexis SA , a JSR Life Sciences company, has named seasoned business development executive Roland Hoffmann-Hecht, PhD, as its new chief business officer.
  • As a member of the companys executive leadership team, Dr. Hoffmann-Hecht will be responsible for all corporate and business development activities and will report directly to Selexis Chief Executive Officer Dirk Lange.
  • Dr. Hoffmann-Hecht joined Selexis from Polpharma Biologics where he was head of business development, CDMO Europe.
  • Previously, he was chief customer officer at CDMO start-up biopharmaceuticals company, Halix B.V.

Samsung Biologics to add mRNA vaccine drug substance manufacturing suite to expand portfolio of services

Retrieved on: 
Monday, May 31, 2021
Companies, Life sciences, Industry economics), Pharmaceutical industry, Samsung, Samsung Biologics, Contract manufacturing organization, Biopharmaceutical, WuXi Biologics

The addition will enable Samsung Biologics to provide end-to-end mRNA vaccine manufacturing services from bulk drug substance to aseptic fill/finish including labeling & packaging, as well as cold chain storage.

Key Points: 
  • The addition will enable Samsung Biologics to provide end-to-end mRNA vaccine manufacturing services from bulk drug substance to aseptic fill/finish including labeling & packaging, as well as cold chain storage.
  • "We are constantly assessing various ways that we can expand and diversify our current business portfolio to better serve the market," said John Rim, CEO of Samsung Biologics.
  • Upon completion of Plant 4, Samsung Biologics will hold a total of 620,000 liters of cell culture capacity and continue to provide end-to-end, start-to-finish services to its clients.
  • Samsung Biologics (KRX: 207940.KS) is a fully integrated CDMO offering state-of-the-art contract development, manufacturing, and laboratory testing services.

Vetter Once Again Wins Axia Best Managed Companies Award

Retrieved on: 
Wednesday, May 26, 2021
Medical devices, Health, Research, Pharmaceutical, Science, Biotechnology, Axia, Contract manufacturing organization

For the second time in a row, Vetter , a global leading contract development and manufacturing organization (CDMO), has won the Axia Best Managed Companies Award.

Key Points: 
  • For the second time in a row, Vetter , a global leading contract development and manufacturing organization (CDMO), has won the Axia Best Managed Companies Award.
  • Every year, Deloitte Private , the prominent German business journal WirtschaftsWoche, Credit Suisse and the Bundesverband der Deutschen Industrie (the Federation of German Industries) select which medium-sized companies are best managed and thus receive the renowned award.
  • The Axia Best Managed Companies Program is established in over 30 countries.
  • Managing Directors Thomas Otto and Peter Soelkner shared, We are honored to receive the Axia Best Managed Companies Award for the second time in a row.

Adare Pharma Solutions Expands Executive Leadership Team

Retrieved on: 
Tuesday, May 25, 2021
Contract manufacturing organization, Pharmaceutical industry

LAWRENCEVILLE, N.J., May 25, 2021 /PRNewswire/ --Adare Pharma Solutions, a specialized Contract Development Manufacturing Organization, announced it has strengthened its executive leadership team with two key hires.

Key Points: 
  • LAWRENCEVILLE, N.J., May 25, 2021 /PRNewswire/ --Adare Pharma Solutions, a specialized Contract Development Manufacturing Organization, announced it has strengthened its executive leadership team with two key hires.
  • "The pharmaceutical industry is undergoing a growing trend toward outsourcing development and commercialization of products," said Vivek Sharma, Adare Pharma Solutions Chief Executive Officer.
  • Previously, he was VP and Global Head of Formulations and Product Development R&D at Piramal Pharma Solutions, a global CDMO.
  • Adare Pharma Solutions is a leading specialty contract development and manufacturing organization (CDMO) and a leading global provider of advanced pharmaceutical technologies, development, and manufacturing.

Moderna and Samsung Biologics Announce Agreement for Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine

Retrieved on: 
Saturday, May 22, 2021
Biotechnology, FDA, Other Health, Health, General Health, Pharmaceutical, Other Science, Research, Infectious diseases, Science, Clinical trials, Companies, Life sciences, Industry economics), Pharmaceutical industry, Samsung, Samsung Biologics, Contract manufacturing organization, Biopharmaceutical

Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing.

Key Points: 
  • Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing.
  • Moderna has been named a top biopharmaceutical employer by Science for the past six years.
  • To learn more, visit www.modernatx.com .\nSamsung Biologics (KRX: 207940.KS) is a fully integrated CDMO offering state-of-the-art contract development, manufacturing, and laboratory testing services.
  • Except as required by law, Samsung Biologics will not update any forward-looking statements to reflect material developments that may occur after the date of this press release.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210522005008/en/\n"

Argenta Enters $30 Million Product Financing Agreement with NovaQuest to Accelerate New Veterinary Product Development

Retrieved on: 
Thursday, May 20, 2021
Health, Research, Pharmaceutical, Science, Veterinary, Biotechnology, Pharmaceutical industry, Life sciences, Biotechnology, Clinical research, Contract research organization, Pharmaceuticals policy, Contract manufacturing organization, Articles, NovaQuest, Argenta, NOVAQUEST, ARGENTA

b'Argenta Limited (\xe2\x80\x9cArgenta\xe2\x80\x9d), the only global contract research organization (CRO) and contract development and manufacturing organization (CDMO) specializing in animal health, and NovaQuest Capital Management (\xe2\x80\x9cNovaQuest\xe2\x80\x9d) announced today a $30 million product financing agreement for the development of several innovative veterinary pharmaceuticals.\nThis press release features multimedia.

Key Points: 
  • b'Argenta Limited (\xe2\x80\x9cArgenta\xe2\x80\x9d), the only global contract research organization (CRO) and contract development and manufacturing organization (CDMO) specializing in animal health, and NovaQuest Capital Management (\xe2\x80\x9cNovaQuest\xe2\x80\x9d) announced today a $30 million product financing agreement for the development of several innovative veterinary pharmaceuticals.\nThis press release features multimedia.
  • Argenta and NovaQuest will look for commercialization partners as the project progresses.\n\xe2\x80\x9cThis is an historic milestone for Argenta and instrumental in advancing our commitment to deliver innovation to the animal health industry.
  • NovaQuest has invested in scores of biopharmaceutical assets across therapeutic areas with a clinical success rate higher than the industry average.
  • Leveraging the core platform, NovaQuest is expanding its strategy to bring much needed capital to the animal health industry.

iBio to Present at the UBS Global Healthcare Virtual Conference

Retrieved on: 
Wednesday, May 19, 2021
Life sciences, Biology, Biotechnology, Pharmaceutical industry, Biopharmaceutical, Pharmacy, Pharming, Contract manufacturing organization

b'BRYAN, Texas, May 19, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE:IBIO) (\xe2\x80\x9ciBio\xe2\x80\x9d or the \xe2\x80\x9cCompany\xe2\x80\x9d), a biotech innovator and biologics contract manufacturing organization, announced today that management will present an update on the Company\xe2\x80\x99s business at the UBS Global Healthcare Virtual Conference on Wednesday, May 26, 2021 at 4:00 p.m Eastern Time.\nThe presentation will be webcast live and archived on the Company\xe2\x80\x99s website at www.ibioinc.com under \xe2\x80\x9cNews and Events\xe2\x80\x9d in the Investors section.\niBio is a global leader in plant-based biologics manufacturing.

Key Points: 
  • b'BRYAN, Texas, May 19, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE:IBIO) (\xe2\x80\x9ciBio\xe2\x80\x9d or the \xe2\x80\x9cCompany\xe2\x80\x9d), a biotech innovator and biologics contract manufacturing organization, announced today that management will present an update on the Company\xe2\x80\x99s business at the UBS Global Healthcare Virtual Conference on Wednesday, May 26, 2021 at 4:00 p.m Eastern Time.\nThe presentation will be webcast live and archived on the Company\xe2\x80\x99s website at www.ibioinc.com under \xe2\x80\x9cNews and Events\xe2\x80\x9d in the Investors section.\niBio is a global leader in plant-based biologics manufacturing.
  • Its FastPharming\xc2\xae System combines vertical farming, automated hydroponics, and novel glycosylation technologies to rapidly deliver high-quality monoclonal antibodies, vaccines, bioinks and other proteins.
  • iBio is developing proprietary products on the FastPharming Platform, which include biopharmaceuticals for the treatment of fibrotic and infectious diseases, amongst others.
  • The Company\xe2\x80\x99s subsidiary, iBio CDMO LLC, provides FastPharming Contract Development and Manufacturing Services, including Glycaneering\xe2\x84\xa2 Development Services for advanced recombinant protein design.

AGC Inc. Receives Best Acquisition Award for Adding the Former MolMed into AGC Biologics

Retrieved on: 
Wednesday, May 19, 2021
Life sciences, Branches of biology, Biology, Molecular biology, Gene delivery, Biotechnology, Pharmaceutical industry, Biopharmaceutical, Pharmacy, Contract manufacturing organization, Vector, Plasmid

b'Seattle, May 19, 2021 (GLOBE NEWSWIRE) -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced their win of the M&A Award for Best Acquisition, Cross-Border into Italy, presented by KPMG, Fineurop Soditic, and others.

Key Points: 
  • b'Seattle, May 19, 2021 (GLOBE NEWSWIRE) -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced their win of the M&A Award for Best Acquisition, Cross-Border into Italy, presented by KPMG, Fineurop Soditic, and others.
  • This award is dedicated to showcasing the best of the Italian M&A market.\n\xe2\x80\x9cWe are incredibly honored to have received this award,\xe2\x80\x9d says AGC Biologics Chief Executive Officer, Patricio Massera.
  • We provide world-class development and manufacture of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), viral vectors and genetically engineered cells.
  • AGC Biologics is the partner of choice.

Argonaut Enhances Manufacturing Capabilities with Major Investment in Lyophilization Facility Expansion

Retrieved on: 
Wednesday, May 19, 2021
Life sciences, Pharmaceutical industry, Biotechnology, Health sciences, Biopharmaceutical, Pharmacy, Vaccine, Contract manufacturing organization, Food and Drug Administration

The new facility will be equipped with upgrades in additional automation to Argonaut\'s existing formulation, fill and finish infrastructure.

Key Points: 
  • The new facility will be equipped with upgrades in additional automation to Argonaut\'s existing formulation, fill and finish infrastructure.
  • This expansion in capacity combined with the technology advancements in lyophilization we have made are dramatically advancing our timelines.
  • "\nTo learn more about services provided by Argonaut Manufacturing Services, visit www.argonautms.com/contact-us/\nArgonaut Manufacturing Services is an FDA-registered cGMP contract manufacturing organization dedicated to providing custom manufacturing and supply chain solutions for biopharmaceutical companies worldwide.
  • Argonaut focuses on biologics manufacturing and does not currently manufacture vaccines with live or attenuated virus, antibody drug conjugates, or potent drugs.\n'

Robert Gadwood to Retire as Kalexsyn CEO

Retrieved on: 
Tuesday, May 18, 2021
Biotechnology, Health, Science, Pharmaceutical, Research, Contract manufacturing organization, Pharmaceutical industry

View the full release here: https://www.businesswire.com/news/home/20210518005874/en/\nThe CEO appointment will be effective today, May 18th, 2021.

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20210518005874/en/\nThe CEO appointment will be effective today, May 18th, 2021.
  • Brian Eklov will focus on Kalexsyn\xe2\x80\x99s sustainable growth, leveraging competencies and operational efficiency within the Dipharma Group, which acquired Kalexsyn in 2018 through its American subsidiary Dipharma, Inc.\nIn 2003, Robert Gadwood and David Zimmerman founded Kalexsyn and over the years the Company has become a world-class Contract Research Organization (CRO), providing innovative chemistry services to the biotechnology and pharmaceutical companies.
  • Nowadays, besides its CRO offering, Kalexsyn provides outstanding CDMO GMP services and manages projects for clinical Phase 1 and early Phase 2 studies,\xe2\x80\x9d said Jorge Nogueira, Chairman of Kalexsyn\xe2\x80\x99s Board of Directors and CEO of Dipharma Francis.
  • \xe2\x80\x9cHe has deep knowledge of the industry dynamics and has been an outstanding R&D director at Kalexsyn since 2016.